RxDoctor Payments Data

Nicole Brinkley

Family · Manchester, TNNPI 1770651093

Payments from drug & device makers

$4,044in general payments, 2019–2025

Across 252 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$715
  • GSK$261
  • AstraZeneca$237
  • Astellas Pharma US Inc$175
  • Otsuka America Pharmaceutical, Inc.$145
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$4,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,044 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide50$80,980
JardianceEmpagliflozin77$80,332
OzempicSemaglutide53$78,730
JanuviaSitagliptin Phosphate71$69,567
FarxigaDapagliflozin Propanediol78$68,432
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$48,226
EliquisApixaban38$42,530
XareltoRivaroxaban40$38,951
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$35,420
Tresiba Flextouch U-200Insulin Degludec36$28,651
KerendiaFinerenone25$23,322
MyrbetriqMirabegron18$17,932
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$14,546
Soliqua 100-33Insulin Glargine/Lixisenatide13$13,274
TradjentaLinagliptin15$12,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,186$159,710103 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$237$111,406139 claims
Boehringer IngelheimJardiance, Tradjenta$107$93,03992 claims
MerckJanuvia$67$69,56771 claims
GSKTrelegy Ellipta, Breo Ellipta$261$59,96880 claims
PfizerEliquis$122$42,53038 claims
BayerKerendia$80$23,32225 claims
Astellas Pharma US IncMyrbetriq$175$17,93218 claims
AbbVieLinzess$715$11,87417 claims
NovartisEntresto$118$8,02611 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$33$6,95612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Manchester

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →